Thyroid Carcinoma Clinical Trial
Official title:
Comparison of Effectiveness and Safety of Thyroidectomy for Thyroid Carcinoma in Patients Undergo Endoscopic Surgery and Those Receive Conversion
Endoscopic thyroidectomy has been used to treat thyroid diseases in China. However, whether this technique is rational to treat thyroid carcinoma is still in controversy. The diagnosis of thyroid carcinoma is predominantly made according to intra-operative frozen section pathological examination in China. In this research, the investigators want to compare clinical index (blood loss, operation duration, number of lymph nodes dissected, complication rates, etc) between patients underwent endoscopic thyroidectomy ( total thyroidectomy) and those underwent conversion to open procedure. The investigators want to evaluate the technical feasibility of endoscopic thyroidectomy for treating thyroid carcinoma.
Status | Not yet recruiting |
Enrollment | 60 |
Est. completion date | June 2012 |
Est. primary completion date | December 2011 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years to 45 Years |
Eligibility |
Inclusion Criteria: - lesion diameter less than 1 cm by ultrasound Exclusion Criteria: - frozen section diagnosis indicates benign lesion |
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
China | Changzheng Hospital | Shanghai | Shanghai |
Lead Sponsor | Collaborator |
---|---|
Second Military Medical University |
China,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | to evaluate the completeness of thyroid resection and clearance of lymph nodes in the central compartment, and to observe the complications such as RLN palsy and hypocalcemia | 1 year after operation | Yes |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02658513 -
Evaluation of Lancet Blood Sampling for Radioiodine Dosimetry in Thyroid Cancer
|
||
Withdrawn |
NCT01707056 -
The Effect of Coffee on the Absorption of Thyroid Hormone in Patients With Thyroid Carcinoma
|
N/A | |
Completed |
NCT00215605 -
Study of XL184 (Cabozantinib) in Adults With Advanced Malignancies
|
Phase 1 | |
Completed |
NCT06439745 -
More Than 50% of the Patients With Clinically Unifocal T1b/Small T2 Node Negative Papillary Thyroid Carcinoma Scheduled for Thyroid Lobectomy May Require Completion Thyroidectomy if the Nodal Status is Evaluated
|
||
Terminated |
NCT04327999 -
Effect of Artificial Tears on Radioiodine Levels in the Nasolacrimal Duct System
|
Phase 2 | |
Completed |
NCT02194920 -
Parathyroid Reimplantation in Forearm Subcutaneous Tissue During Thyroidectomy: a Simple Way to Avoid Ipoparathyroidism and Evaluate Graft Function
|
N/A | |
Enrolling by invitation |
NCT06095362 -
Thyroid Cancer and Central Lymph Node Metastases Detection Using Bevacizumab-IRDye800CW
|
Phase 1 | |
Not yet recruiting |
NCT05949424 -
OPTI - DOSE: Optimal Dosing of Oral Anticancer Drugs in Older Adults
|
Phase 4 | |
Active, not recruiting |
NCT02145143 -
Enhancing Radioiodine (RAI) Incorporation Into BRAF Mutant, RAI-Refractory Thyroid Cancers With the BRAF Inhibitor Vemurafenib: A Pilot Study
|
N/A | |
Terminated |
NCT01865838 -
A Study Into the Effect of Seprafilm in Open Total Thyroidectomy
|
N/A | |
Recruiting |
NCT00749697 -
Radioiodine Dosimetry Protocol for Thyroid Cancer Metastases
|
N/A | |
Enrolling by invitation |
NCT04411290 -
Malignancy Predictors, Bethesda and TI-RADS Scores Correlated With Final Histopathology in Thyroid Diseases
|
||
Completed |
NCT01813136 -
Phase II Study of the Optimal Scheme of Administration of Pazopanib in Thyroid Carcinoma
|
Phase 2 | |
Recruiting |
NCT05668962 -
Restor. I-131 Upt. + Selpercatinib in RET F-P RAI-R TC
|
Phase 2 | |
Active, not recruiting |
NCT02185560 -
Prospective, Non-interventional, Post-authorization Safety Study That Includes All Patients Diagnosed as Unresectable Differentiated Thyroid Carcinoma and Treated With Sorafenib
|
||
Completed |
NCT04462471 -
Vemurafenib Plus Copanlisib in Radioiodine-Refractory (RAIR) Thyroid Cancers
|
Phase 1 | |
Completed |
NCT01433809 -
Biomarkers to Distinguish Benign From Malignant Thyroid Neoplasm
|
N/A | |
Recruiting |
NCT00929318 -
Influence of Thyroid Hormones on the Woundhealing Process
|
N/A | |
Completed |
NCT05178186 -
Impact of the COVID-19 Pandemic on Surgery for Thyroid Cancer
|
N/A | |
Completed |
NCT02773667 -
Renal Tracer Elimination in Thyroid Cancer Patients Treated With 131-Iodine
|